Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis.

ABSTRACT:

Objective

Biologic drug therapies represent a huge advance in the treatment of rheumatoid arthritis (RA). However, very good disease control is achieved in only 30% of patients, making identification of biomarkers of response a research priority. We undertook this study to test our hypothesis that differential DNA methylation patterns may provide biomarkers predictive of response to tumor necrosis factor inhibitor (TNFi) therapy in patients with RA.

Methods

An epigenome-wide association study was performed on pretreatment whole blood DNA from patients with RA. Patients who displayed good response (n = 36) or no response (n = 36) to etanercept therapy at 3 months were selected. Differentially methylated positions were identified using linear regression. Variance of methylatio

SUBMITTER: Plant D 

PROVIDER: S-EPMC4914881 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature